When was BioAtla founded?

BioAtla was founded in 2007 and raised its 1st funding round 7 years after it was founded.

Where is BioAtla located?

BioAtla is headquartered in San Diego, United States. It is registered at San Diego, California.

Who is the current CEO of BioAtla?

Jay Short of BioAtla. They have also founded 1 company.

How many employees does BioAtla have?

As of Apr 30, 2026, the latest employee count at BioAtla is 40.

Is BioAtla a funded company?

BioAtla is a funded company, having raised a total of $162M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 11, 2014.

When was the latest funding round of BioAtla?

BioAtla's latest funding was a $***** Series D round on Jul 15, 2020, with participation from 7 investors.

Where does BioAtla rank among its competitors?

BioAtla ranks 178th amongst 3393 active competitors, of which 1181 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Moderna, which secured $590M in Jan, 2025.

Who are the top competitors of BioAtla?

BioAtla's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Moderna secured the most recent funding round in January, 2025.

BioAtla - 2026 Company Profile, Team, Funding, Competitors & Financials

BioAtla is a public company based in San Diego (United States), founded in 2007 by Jay Short. It operates as a Developer of immunotherapies for cancer using active biologics platform. BioAtla has raised $162M in funding from HBM Healthcare Investments and Soleus Capital. The company has 3393 active competitors, including 1181 funded and 793 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of immunotherapies for cancer using active biologics platform. The platform technology is known as Conditionally Active Biologics (CABs). CAB-designed monoclonal antibodies selectively bind their antigen in the context of diseased tissue by exploiting the unique microenvironment of diseased vs normal tissue. Its pipeline includes antibodies for cancer, hematological cancer, and autoimmune disease.

Website: bioatla.com
Registered Address: San Diego, California

Key Metrics

Founded Year

2007

Location

San Diego, United States

Stage

Public

Total Funding

$162M in 5 rounds

Latest Funding Round

Series D, Jul 15, 2020, $*****

Investors

HBM Healthcare Investments & 16 more

Ranked

178^th among 3393 active competitors

Employee Count

40 as on Apr 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3239 more

Exit Details

Public

View BioAtla's full profile

BioAtla is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Bioatla, Inc. CIN: 1826892 , United States, Active	Mar 14, 2019	-	-	-
Bioatla Llc CIN: 208760096 , United States, Active	Dec 31, 2006	-	77 (As on Dec 31, 2024)	-

BioAtla got listed on Dec 16, 2020.

Click here to take a look at BioAtla's IPO in detail

BioAtla has raised a total funding of $162M over 5 rounds. Its first funding round was on Apr 11, 2014. Its latest funding round was a Series D round on Jul 15, 2020 for $*****. 7 investors participated in its latest round. BioAtla has 17 institutional investors.

Here is the list of recent funding rounds of BioAtla:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 15, 2020	3215278	Series D	1637559	1715958	1371403	5938118
Apr 01, 2016	5453577	Grant (prize money)	4940777	2981164	2237721	HHS
Jan 11, 2016	2399780	Series B	8338255	1345324	6622545	3425299

Access funding benchmarks and valuations. Sign up today!

View details of BioAtla's funding rounds and investors

The founders of BioAtla is Jay Short. Jay Short is the CEO of BioAtla.

Here are the details of BioAtla's key team members:

Jay Short: Chairman, CEO and Cofounder of BioAtla.

View details of BioAtla's Founder profiles and Board Members

BioAtla's employee count trend

BioAtla has 40 employees as of Apr 26. Here is BioAtla's employee count trend over the years:

Uncover BioAtla's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of BioAtla include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of BioAtla, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating human disease conditions	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
4th	Senti Biosciences 2016, San Francisco (United States), Public	Developer of cell-based therapies for cancer treatment	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
5th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
7th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 18 others	72/100
10th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, Astrazeneca & 31 others	71/100
178th	BioAtla 2007, San Diego (United States), Public	Developer of immunotherapies for cancer using active biologics platform	$162M	HTIF, Boxer Capital & 15 others	60/100